Showing 5121-5130 of 5957 results for "".
- Schwind Receives CE Mark Approval for the Schwind ATOS Femtosecondhttps://modernod.com/news/schwind-receives-ce-mark-approval-for-the-schwind-atos-femtosecond/2478006/Schwind eye-tech-solutions announced that it has received CE Mark approval for the Schwind ATOS femtosecond laser. This enables refractive surgeons to offer their patients SmartSight, the latest generation of lenticul
- Women in Ophthalmology (WIO) 2020 Summer Symposium Goes Virtualhttps://modernod.com/news/women-in-ophthalmology-wio-2020-summer-symposium-goes-virtual/2477999/Due to the recent rise in COVID-19 cases in Florida, Women in Ophthalmology (WIO) has decided to is move its Summer Symposium to an all-virtual platform on August 21-23, 2020. “In classic WIO fashion, we have planned an innovative meeting like no other with 24 hours of CME, scientifi
- Biogen Boosts Gene Therapy Strategy With Harvard Pact Focused on Inherited Eye Diseasehttps://modernod.com/news/biogen-boosts-gene-therapy-strategy-with-harvard-pact-focused-on-inherited-eye-disease/2477996/Mutations in more than 270 genes have been implicated in inherited eye diseases like retinitis pigmentosa. Now, Biogen has formed a research pact with Harvard’s Massachusetts Eye and Ear that’s aimed at developing a gene therapy to help some patients with these blinding diseases, according to a F
- New $1-Billion Fund Aims to Rescue “Collapsing” Antibiotic Pipelinehttps://modernod.com/news/new-1-billion-fund-aims-to-rescue-collapsing-antibiotic-pipeline/2477997/More than 20 biopharmaceutical companies on Thursday joined forces to invest nearly $1 billion in a new fund aimed at supporting the development of antibiotics to address the rapid rise of antimicrobial resistance (AMR). The AMR Action Fund, spearheaded by the International Federation of Ph
- BD Launches 15-minute Coronavirus Antigen Test, Promises Millions in Coming Monthshttps://modernod.com/news/bd-launches-15-minute-coronavirus-antigen-test-promises-millions-in-coming-months/2477994/The FDA granted an emergency authorization to a portable coronavirus antigen test developed by BD, similar to a rapid flu test, designed to allow hospitals, doctors’ offices, urgent care centers, and retail pharmacies to examine a person showing symptoms in about 15 minutes, accor
- LumiThera Closes Series C Round of Financinghttps://modernod.com/news/lumithera-closes-series-c-round-of-financing/2477993/LumiThera announced it has completed its Series C financing. The company raised approximately $14 million to support further commercialization of its Valeda Light Delivery System for the treatment for dry age-related macular degeneration (AMD), to complete its LIGHTS
- Accelmed Partners Completes Acquisition of TearLabhttps://modernod.com/news/accelmed-partners-completes-acquisition-of-tearlab/2477991/Private equity firm Accelmed Partners II (AP-II) completed its $25 million acquisition of dry eye device maker TearLab. As a newly formed private company, TearLab is now positioned to pursue further development of its next-generation Discovery platform and seek out targeted acquisition opp
- Laboratory Studies Confirm Betadine Antiseptic Products’ Effectiveness Against COVID-19 Virushttps://modernod.com/news/laboratory-studies-confirm-betadine-antiseptic-products-effectiveness-against-covid-19-virus/2477989/Mundipharma announced that laboratory testing at the Duke-NUS Medical School in Singapore has confirmed the effectiveness of its Betadine antiseptic products against the novel coronavirus (SARS-CoV-2). Testing has demonstrated Betadine strong in-vitro virucidal activity, killing 99.99% of
- Novavax Gains $1.6 Billion in Funding for COVID-19 Vaccine Candidatehttps://modernod.com/news/novavax-gains-1-6-billion-in-funding-for-covid-19-vaccine-candidate/2477984/Novavax announced that it has been awarded $1.6 billion by the US government to progress development of NVX CoV2373 and potentially deliver 100 million doses of the COVID-19 vaccine as early as late 2020. NVX‑CoV2373 consists of a stable, prefusion protein made using Novavax’s nanop
- Palatin Technologies Announces Reinitiation of Enrollment of Phase 2 Study With PL9643 for the Treatment of Dry Eye Diseasehttps://modernod.com/news/palatin-technologies-announces-reinitiation-of-enrollment-of-phase-2-study-with-pl9643-for-the-treatment-of-dry-eye-disease/2477985/Palatin Technologies announced reinitiation of enrollment of its phase 2 study with PL9643 for the treatment of dry eye disease (DED). After pausing patient recruitment to ensure patient safety during the initial phases of the COVID-19 pandemic, Palatin has commenced patient recruitment in